Arsenic trioxide
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Arsenic trioxide and local guidelines before prescribing.
Cytotoxic
Mechanism
Induces differentiation and apoptosis of promyelocytic cells.
Uses
Acute promyelocytic leukaemia.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Differentiation syndrome, QT prolongation, hepatotoxicity, fever.
Interactions
QT-prolonging drugs.
Contraindications and cautions
QT prolongation
Monitoring
ECG, potassium, magnesium
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Caution in renal impairment
Overdose and reversal
Supportive
Special advice
ECG and electrolyte monitoring; urgent treatment of differentiation syndrome with steroids.
More from the textbook: uses, cautions and other points
- All-trans retinoic acid and arsenic trioxide | Acute promyelocytic leukaemia | Differentiation syndrome (fever, breathlessness, fluid - dexamethasone); arsenic - QT prolongation
Haematology: Anatomy Physiology and Pharmacology - Treatment: ATRA plus arsenic trioxide (chemotherapy-free for low and intermediate risk); chemotherapy added for high-risk disease.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - ATRA + arsenic trioxide | APL - start ATRA on suspicion; differentiation syndrome (dexamethasone); arsenic prolongs QT.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Confirm PML–RARA; then ATRA plus arsenic trioxide; watch for differentiation syndrome.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia